Humana Inc vs Starbucks Corp — how do they compare? Humana Inc trades at $447.4 (market cap $46.49B), while Starbucks Corp trades at $93.24 (market cap $106.26B). The key difference: Starbucks Corp is far larger — about 2.3× Humana Inc's market cap, and Starbucks Corp pays the higher dividend (2.7%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Starbucks Corp for 190 Days on average.
| HUM | SBUX | |
|---|---|---|
Market Cap | $46.49B | $106.26B |
Volume | 2,567,704 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $409.85 | $108.55 |
52-Week Low | $163.67 | $78.46 |
Typical Hold Time | 53 Days | 190 Days |
Enterprise Value | $53.84B | $125.08B |
Dividend Yield | 0.91% | 2.7% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
Starbucks (SBUX) trades at $93.58, down 2.63% on the day, as the company navigates a strategic restructuring with 250 North American store closures. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Fundamentally, SBUX maintains stable revenue growth but faces margin compression, with net income declining to $1.86B in 2025. Analyst consensus remains positive with a $115.50 price target, though recent news highlights operational challenges and geopolitical tensions.
The outlook for SBUX balances near-term headwinds from restructuring costs against long-term growth potential in international markets. Investment opportunities include strong brand equity and dividend consistency, while risks involve labor relations, Chinese market exposure, and execution of the store optimization strategy. The current valuation at 53.88x P/E requires sustained earnings recovery to justify upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →